PharmacoEconomics & Outcomes News

, Volume 832, Issue 1, pp 17–17 | Cite as

Insulin degludec good value for money in T2DM with high CV risk

Clinical study


  1. Pollock RF, et al. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). Applied Health Economics and Health Policy : 2 Jul 2019. Available from: URL:

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations